Recognized with a Nobel Prize in 2020, CRISPR has opened the floodgates for a new era of gene editing therapies, promising to transform genetic disease treatments. With a well-established early field of genomics research, drug developers and researchers have been busy establishing the next-generation CRISPR toolkit, including Cas nucleases, base and prime editing technologies, and innovative delivery platforms.

The 3^rd CRISPR 2.0 Summit is devoted to showcasing the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy, minimizing off-target effects & enabling efficient tissue-specific delivery to help you progress your program into and through the clinic.

Across three days of content, co-designed with 27+ industry thought leaders, this streamlined one-track summit will unite 100+ key players in the CRISPR space, from large pharma to ground-breaking biotech, academics to exciting service providers, all with the purpose of paving a way forward to market for your CRISPR gene editing program.

Here’s a snapshot of our 27+ thought leaders:

• Kiran Musunuru, Professor of Medicine, Perelman School of Medicine, University of Pennsylvania
• Amy Simon, Chief Medical Officer, Beam Therapeutics
• Jane Grogan, Chief Scientific Officer, Graphite Bio
• Liron Walsh, Head of Development; In Vivo Programs, Intellia Therapeutics
• Jeremy Duffield, Chief Scientific Officer, Prime Medicine
• Eric B. Kmiec, Executive Director & Chief Scientific Officer, Christiana Care Gene Editing Institute
• Rafi Emmanuel, Senior Vice President – Research & Development, Emendo Biotherapeutics
• John Murphy, Chief Scientific Officer, Arbor Biotechnologies
• Inge Yung-Chih Cheng, Principal Scientist, Pfizer
• Joey Riepsaame, Head of Genome Engineering, University of Oxford
• Rammohan Devulapally, Principal Scientist, GenEdit

Be part of the community as we dive deep into:

• Refining non-viral tissue targeted CRISPR delivery methods for maximized safety and efficacy, with help from GenEdit and the latest research from the David Liu Lab.
• From bench to bedside: translating basic CRISPR research into a viable therapeutic product, with Beam Therapeutics
• Leverage the latest base and prime editing technology for enhanced precision treatment of inherited disorders, with Prime Medicine and UC Irvine.

And more!

Join this unmissable summit and network experts from the likes of Beam Therapeutics, The David Liu Lab, Pfizer, GenEdit, AZ, GSK, Caribou Biosciences, Prime Medicine, Intellia Therapeutics and many more.

To know more visit: https://ter.li/vumobp